Somewhat Positive Media Coverage Somewhat Unlikely to Impact Kite Pharma (NASDAQ:KITE) Stock Price

News stories about Kite Pharma (NASDAQ:KITE) have been trending somewhat positive recently, according to Accern Sentiment Analysis. The research group identifies negative and positive news coverage by analyzing more than twenty million blog and news sources. Accern ranks coverage of companies on a scale of negative one to one, with scores closest to one being the most favorable. Kite Pharma earned a news sentiment score of 0.21 on Accern’s scale. Accern also gave news articles about the biopharmaceutical company an impact score of 45.694856890492 out of 100, indicating that recent news coverage is somewhat unlikely to have an impact on the stock’s share price in the near term.

Here are some of the media stories that may have impacted Accern Sentiment Analysis’s rankings:

Kite Pharma (NASDAQ:KITE) opened at $179.99 on Tuesday. The company has a market capitalization of $10,280.00 and a price-to-earnings ratio of -26.09. Kite Pharma has a 52-week low of $39.82 and a 52-week high of $179.99.

COPYRIGHT VIOLATION WARNING: This report was originally published by The Ledger Gazette and is the property of of The Ledger Gazette. If you are viewing this report on another site, it was copied illegally and reposted in violation of United States and international trademark & copyright law. The original version of this report can be viewed at https://ledgergazette.com/2018/01/16/kite-pharma-kite-earning-somewhat-positive-press-coverage-analysis-shows.html.

Kite Pharma Company Profile

Kite Pharma, Inc is a clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of cancer immunotherapy products to target and kill cancer cells. The Company offers engineered autologous cell therapy, which is an approach to the treatment of cancer. Its therapy involves modifying a patient’s T cells outside the patient’s body, or ex vivo, causing the T cells to express chimeric antigen receptors (CARs), or T cell receptors (TCRs), and then reinfusing the engineered T cells back into the patient.

Insider Buying and Selling by Quarter for Kite Pharma (NASDAQ:KITE)

Receive News & Ratings for Kite Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kite Pharma and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply